Prathyusha Duraibabu
Organogenesis HoldingsAbout Prathyusha Duraibabu
Independent director since 2021; age 46. Chief Financial Officer at Sangamo Therapeutics (since June 2021), previously VP Finance (2019–2021) and Corporate Controller at Pacific Biosciences (2010–2019). B.S. in Accounting (Oxford Brookes University), MBA (San Jose State University), and CPA (California). Recognized by the board as an Audit Committee Financial Expert.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sangamo Therapeutics, Inc. | Chief Financial Officer | Jun 2021–present | Oversees finance operations at a genomic medicine company |
| Sangamo Therapeutics, Inc. | Vice President, Finance | Mar 2019–Jun 2021 | Finance leadership; FP&A and controls |
| Pacific Biosciences of California, Inc. | Corporate Controller | Jun 2010–Mar 2019 | Responsible for global financial operations, strategy, audit, and tax |
External Roles
| Organization | Role | Type | Responsibilities |
|---|---|---|---|
| Sangamo Therapeutics, Inc. | Chief Financial Officer | Public company | Corporate finance leadership; genomic medicine sector |
Board Governance
- Committee memberships:
- Audit Committee member; board determined she meets Nasdaq and SEC independence standards and qualifies as an Audit Committee Financial Expert; committee met 6 times in FY2024.
- Compensation Committee member; committee met 8 times in FY2024; all members deemed independent.
- Attendance and engagement:
- Board met 7 times in FY2024; no director (other than Alan A. Ades) attended fewer than 75% of meetings and relevant committees (implies ≥75% attendance for Duraibabu).
- Leadership context: Lead Independent Director (Leibowitz); CEO also serves as Board Chair (combined role).
Fixed Compensation (Independent Director Program; FY2024)
| Component | Amount ($) | Notes |
|---|---|---|
| Annual director retainer | 55,000 | Independent directors |
| Audit Committee member fee | 10,000 | Non-chair member |
| Compensation Committee member fee | 10,000 | Non-chair member |
| Total cash earned (FY2024) | 75,000 | Reported for Duraibabu |
Performance Compensation (Independent Director Equity; FY2024)
| Grant Date | Award Type | Units/Shares | Grant-Date Fair Value ($) | Vesting Schedule |
|---|---|---|---|---|
| Feb 2024 | RSUs | 51,020 | 175,000 | One-year vest; vested Feb 15, 2025 (typical annual director grant) |
Directors receive time-based RSUs; no performance-based vesting or options for Duraibabu disclosed. Independent director awards accelerate upon Change in Control if serving immediately prior to the event (single-trigger acceleration for time-based equity).
Company Performance Metrics (context for Compensation Committee oversight; FY2024)
| Metric | Minimum (75%) | Target (100%) | Exceed (150%) | Maximum (200%) | Actual | Attainment |
|---|---|---|---|---|---|---|
| Net Revenue ($) | 450,000,000 | 470,000,000 | 490,000,000 | 510,000,000 | 482,000,000 | 130% |
| Gross Margin (%) | 76.0% | 77.0% | 77.5% | 78.0% | 76.1% | 77% |
| Adjusted EBITDA ($, excl. clinical) | 43,000,000 | 53,000,000 | 63,000,000 | 73,000,000 | 64,100,000 | 155% |
Other Directorships & Interlocks
| Company | Role | Interlock/Conflict Note |
|---|---|---|
| Sangamo Therapeutics, Inc. | CFO | No compensation committee interlocks disclosed by ORGO; committee members are independent. |
Expertise & Qualifications
- CPA (California); designated Audit Committee Financial Expert by the board.
- Over two decades optimizing financial operations, organizational change, and compliance in biotech/tech.
- Education: B.S. Accounting (Oxford Brookes), MBA (San Jose State).
Equity Ownership
| Category | Shares/Units | Notes |
|---|---|---|
| Beneficial ownership (Apr 11, 2025) | 148,644 | Less than 1% of shares outstanding; ~0.12% based on 126,853,536 shares outstanding |
| Stock awards outstanding (Dec 31, 2024) | 51,020 RSUs | Annual director grant before Feb 15, 2025 vesting |
| Options (Dec 31, 2024) | 0 | No options outstanding for Duraibabu |
| Hedging/margin policy | Prohibited | Company policy bans short sales, hedging, and purchasing on margin |
Governance Assessment
-
Strengths
- Independent director with deep finance credentials; Audit Committee Financial Expert designation elevates audit oversight quality.
- Active committee participation (Audit and Compensation) with regular meetings; attendance at least 75%.
- Director pay mix skews to equity (70% RSUs, 30% cash for FY2024), aligning interests with shareholders.
- Company-wide prohibitions on hedging/margin and formal clawback policy support investor-alignment and accountability.
-
Watchpoints / Potential Red Flags
- Preferred Director (Avista) sits on Compensation and Nominating committees; while disclosed as independent, investor influence is notable given Avista’s rights and ownership—monitor committee dynamics and decisions.
- Single-trigger acceleration of time-based director equity upon Change in Control could reduce alignment during transaction scenarios.
- ORGO’s significant stockholder group controls ~40.3% and Avista has convertible preferred with governance rights—board independence and minority shareholder protections should be monitored in contested decisions.
-
Shareholder Sentiment
- Say-on-pay approval ~92% at 2024 Annual Meeting (executive compensation), indicating general support for compensation oversight (relevant to Compensation Committee role).
-
Related-Party Transactions
- Audit Committee explicitly reviews related-party transactions per policy; no Duraibabu-specific related-party transactions disclosed in the sections reviewed. Continue monitoring annual proxy disclosures.